B-cell acute lymphoblastic leukemia (B-ALL), characterized by the clonal expansion of immature lymphoblastic cells, is traditionally treated with lengthy chemotherapy followed by allogeneic stem cell transplantation (aSCT) for high-risk patients. However, patients with relapsed or refractory B-ALL still present a dismal prognosis.
Approximately 10%-15% of breast cancer cases are classified within the invasive lobular carcinoma (ILC) type, and a great majority of them are estrogen receptor-positive (ER+). Despite the significant clinical differences between ILCs and invasive carcinoma of no special type (or ductal), ICL treatment still follows ductal paradigms, relying on endocrine therapy plus surgery and radiotherapy.
Great Novel Therapeutics Biotech & Medicals Corp.’s epigenetic immunoactivator, GNTbm-38, has received IND clearance from the FDA, enabling initiation of a phase I trial in the U.S.
Kestrel Therapeutics Inc. has obtained IND approval from the FDA for KST-6051, an oral, small-molecule pan-KRAS inhibitor being developed for the treatment of KRAS-driven cancers.
Haisco Pharmaceutical Group Co. Ltd. has reported fibroblast growth factor receptor 2 (FGFR2) and FGFR3 inhibitors potentially useful for the treatment of cancer.
A Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. patent describes the discovery of new proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS-targeting moiety. They are reported to be useful for the treatment of cancer.
Chengdu Kendite Biomedical Technology Co. Ltd. has synthesized pyrimidopyrazole compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors. They are reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease, dermatological and inflammatory disorders.
Neuroblastoma cells harbor a pattern of chromosomal aberrations that include chromosomes 1p and 11q deletions and 2p and 17q gains, as well as MYCN gene amplification with MYC overexpression. Recent research has identified RuvB-like 1 (RUVBL1) and RUVBL2 to be key mediators of the therapeutic response to a promising strategy such as serine/threonine-protein kinase ATR inhibition.
Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have patented 20-hydroxyeicosatetraenoic acid (20-HETE) production inhibitors. They are reported to be useful for the treatment of cancer, obesity, diabetes, Alzheimer’s and Parkinson’s disease, osteoporosis, cardiovascular and cerebrovascular disorders, among others.
RSS
